Bessemer Group Inc. Sells 11,565 Shares of Insulet Corporation (NASDAQ:PODD)

Bessemer Group Inc. lessened its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 59.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,794 shares of the medical instruments supplier's stock after selling 11,565 shares during the quarter. Bessemer Group Inc.'s holdings in Insulet were worth $2,047,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. SBI Securities Co. Ltd. acquired a new position in Insulet during the 4th quarter worth approximately $36,000. Itau Unibanco Holding S.A. purchased a new position in shares of Insulet in the fourth quarter valued at $42,000. SRS Capital Advisors Inc. grew its holdings in Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 56 shares in the last quarter. Assetmark Inc. increased its stake in Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after buying an additional 246 shares during the period. Finally, Coppell Advisory Solutions LLC lifted its holdings in Insulet by 135.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock worth $74,000 after buying an additional 162 shares in the last quarter.

Insider Transactions at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president owned 23,180 shares in the company, valued at $7,382,134.60. This trade represents a 18.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.39% of the company's stock.

Insulet Stock Up 0.3%

NASDAQ PODD traded up $1.01 on Wednesday, reaching $301.00. The stock had a trading volume of 456,081 shares, compared to its average volume of 715,635. The business has a 50 day moving average price of $300.32 and a 200 day moving average price of $278.15. Insulet Corporation has a 1 year low of $173.00 and a 1 year high of $329.33. The company has a market capitalization of $21.18 billion, a price-to-earnings ratio of 54.15, a P/E/G ratio of 2.80 and a beta of 1.35. The company has a current ratio of 4.47, a quick ratio of 3.63 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The business had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. Insulet's revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.73 EPS. On average, analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group initiated coverage on Insulet in a research note on Friday, May 30th. They set a "buy" rating and a $380.00 price objective for the company. Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target for the company in a research note on Tuesday, May 13th. Royal Bank Of Canada began coverage on Insulet in a research note on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective on the stock. Wall Street Zen lowered Insulet from a "buy" rating to a "hold" rating in a research report on Saturday, June 14th. Finally, Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $321.00.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.